Favipiravir (T-705), a novel viral RNA polymerase inhibitor

Antiviral Research

Volumn 100, Issue 2, 2013, Pages 446-454

  Furuta, Yousuke ^a   Gowen, Brian B ^b   Takahashi, Kazumi ^a   Shiraki, Kimiyasu ^c   Smee, Donald F ^b   Barnard, Dale L ^b  

^a TOYAMA CHEMICAL CO LTD   (Japan)

^b UTAH STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Favipiravir; Influenza; RNA viruses; RNA dependent RNA polymerase; T 705

Indexed keywords

FAVIPIRAVIR; OSELTAMIVIR; PLACEBO; ZANAMIVIR; AMIDE; ANTIVIRUS AGENT; DNA DIRECTED RNA POLYMERASE; ENZYME INHIBITOR; PYRAZINE DERIVATIVE;

ALPHA VIRUS; ANTIVIRAL ACTIVITY; BUNYAVIRUS; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG STRUCTURE; FLAVIVIRUS; IN VITRO STUDY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NONHUMAN; NOROVIRUS; PICORNAVIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRUS REPLICATION; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; INFLUENZA; ISOLATION AND PURIFICATION; JAPAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RNA VIRUS; RNA-DEPENDENT RNA POLYMERASE; T-705; UNITED STATES;

ALPHAVIRUS; AVES; ENTEROVIRUS; ORTHOMYXOVIRIDAE; PARAMYXOVIRIDAE; PHLEBOVIRUS; RESPIRATORY SYNCYTIAL VIRUS; RHINOVIRUS; RNA VIRUSES; WESTERN EQUINE ENCEPHALOMYELITIS VIRUS;

FAVIPIRAVIR; INFLUENZA; RNA VIRUSES; RNA-DEPENDENT RNA POLYMERASE; T-705;

AMIDES; ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DNA-DIRECTED RNA POLYMERASES; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; JAPAN; PYRAZINES; RNA VIRUSES; UNITED STATES;

EID: 84885448756     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.09.015     Document Type: Review

References (33)

1. T. Baranovich, S.S. Wong, J. Armstrong, H. Marjuki, R.J. Webby, R.G. Webster, and E.A. Govorkova T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro J. Virol. 87 2013 3741 3751
2. K.K. Buys, K.H. Jung, D.F. Smee, Y. Furuta, and B.B. Gowen Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir Antivir. Chem. Chemother. 21 2011 193 200
3. Y. Furuta, K. Takahashi, Y. Fukuda, M. Kuno, T. Kamiyama, K. Kozaki, N. Nomura, H. Egawa, S. Minami, Y. Watanabe, H. Narita, and K. Shiraki In vitro and in vivo activities of anti-influenza virus compound T-705 Antimicrob. Agents Chemother. 46 2002 977 981
4. Y. Furuta, K. Takahashi, M. Kuno-Maekawa, H. Sangawa, S. Uehara, K. Kozaki, N. Nomura, H. Egawa, and K. Shiraki Mechanism of action of T-705 against influenza virus Antimicrob. Agents Chemother. 49 2005 981 986
5. Y. Furuta, K. Takahashi, K. Shiraki, K. Sakamoto, D.F. Smee, D.L. Barnard, B.B. Gowen, J.G. Julander, and J.D. Morrey T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections Antiviral Res. 82 2009 95 102
6. B.B. Gowen, D.F. Smee, M.H. Wong, J.O. Hall, K.H. Jung, K.W. Bailey, J.R. Stevens, Y. Furuta, and J.D. Morrey Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin PLoS One 3 2008 e3725
7. B.B. Gowen, M.H. Wong, K.H. Jung, A.B. Sanders, M. Mendenhall, K.W. Bailey, Y. Furuta, and R.W. Sidwell In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections Antimicrob. Agents Chemother. 51 2007 3168 3176
8. B.B. Gowen, M.H. Wong, K.H. Jung, D.F. Smee, J.D. Morrey, and Y. Furuta Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models Antiviral Res. 86 2010 121 127
9. Y. Itoh, K. Shinya, M. Kiso, T. Watanabe, Y. Sakoda, M. Hatta, Y. Muramoto, D. Tamura, Y. Sakai-Tagawa, T. Noda, S. Sakabe, M. Imai, Y. Hatta, S. Watanabe, C. Li, S. Yamada, K. Fujii, S. Murakami, H. Imai, S. Kakugawa, M. Ito, R. Takano, K. Iwatsuki-Horimoto, M. Shimojima, T. Horimoto, H. Goto, K. Takahashi, A. Makino, H. Ishigaki, M. Nakayama, M. Okamatsu, K. Takahashi, D. Warshauer, P.A. Shult, R. Saito, H. Suzuki, Y. Furuta, M. Yamashita, K. Mitamura, K. Nakano, M. Nakamura, R. Brockman-Schneider, H. Mitamura, M. Yamazaki, N. Sugaya, M. Suresh, M. Ozawa, G. Neumann, J. Gern, H. Kida, K. Ogasawara, and Y. Kawaoka In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses Nature 460 2009 1021 1025
10. Z. Jin, L.K. Smith, V.K. Rajwanshi, B. Kim, and J. Deval The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5′-triphosphate towards influenza A virus polymerase PLoS One 8 2013 e68347
11. Jochmans, D., Segura, G.N., Delang, L., Pastprino, B., Querat, G., Dallmeier, K., Bello, F., Tas, A., Snijder, E., de Lamballerie, X., Martina, B., Froeyen, M., Neyts, J., van Hemert, M., Leyssen, P., 2013. Inhibition of Chikungunya virus replication by T-705 (favipiravir) and identification of resistance associated mutations in the RNA-dependent RNA polymerase. 26th International Conference on Antiviral Research Poster 169.
12. J.G. Julander, K. Shafer, D.F. Smee, J.D. Morrey, and Y. Furuta Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106 Antimicrob. Agents Chemother. 53 2009 202 209
13. J.G. Julander, D.F. Smee, J.D. Morrey, and Y. Furuta Effect of T-705 treatment on western equine encephalitis in a mouse model Antiviral Res. 82 2009 169 171
14. M. Kiso, K. Takahashi, Y. Sakai-Tagawa, K. Shinya, S. Sakabe, Q.M. Le, M. Ozawa, Y. Furuta, and Y. Kawaoka T-705 (favipiravir) activity against lethal H5N1 influenza A viruses Proc. Natl. Acad. Sci. USA 107 2010 882 887
15. J.B. McCormick, I.J. King, P.A. Webb, C.L. Scribner, R.B. Craven, K.M. Johnson, L.H. Elliott, and R. Belmont-Williams Lassa fever. Effective therapy with ribavirin N. Engl. J. Med. 314 1986 20 26
16. M. Mendenhall, A. Russell, T. Juelich, E.L. Messina, D.F. Smee, A.N. Freiberg, M.R. Holbrook, Y. Furuta, J.C. de la Torre, J.H. Nunberg, and B.B. Gowen T-705 (favipiravir) inhibition of arenavirus replication in cell culture Antimicrob. Agents Chemother. 55 2011 782 787
17. M. Mendenhall, A. Russell, D.F. Smee, J.O. Hall, R. Skirpstunas, Y. Furuta, and B.B. Gowen Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever PLoS Negl. Trop. Dis. 5 2011 e1342
18. M.L. Moraz, and S. Kunz Pathogenesis of arenavirus hemorrhagic fevers Expert Rev. Anti. Infect. Ther. 9 2011 49 59
19. J.D. Morrey, B.S. Taro, V. Siddharthan, H. Wang, D.F. Smee, A.J. Christensen, and Y. Furuta Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents Antiviral Res. 80 2008 377 379
20. L. Naesens, L. Guddat, D. Keough, A.B. van Kuilenburg, J. Meijer, J.V. Voorde, and J. Balzarini Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir) Mol. Pharmacol. 2013 10.1124/mol.113.087247
21. J. Rocha-Pereira, D. Jochmans, K. Dallmeier, P. Leyssen, M.S. Nascimento, and J. Neyts Favipiravir (T-705) inhibits in vitro norovirus replication Biochem. Biophys. Res. Commun. 424 2012 777 780
22. Sangawa, H., Komeno, T., Nishikawa, H., Yoshida, A., Takahashi, K., Nomura, N., Furuta, Y., 2013. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob. Agents Chemother. 2013. PMID:23917318 [Epub ahead of print] < http://aac.asm.org/content/early/2013/ 07/30/AAC.00649-13.full.pdf+html >.
23. T.G. Sheu, V.M. Deyde, M. Okomo-Adhiambo, R. Garten, X. Xu, R. Bright, E. Butler, T.R. Wallis, A.I. Klimov, and L.V. Gubareva Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide in 2004-2008 Antimicrob. Agents Chemother. 52 2008 3284 3292
24. R.W. Sidwell, D.L. Barnard, C.W. Day, D.F. Smee, K.W. Bailey, M.H. Wong, J.D. Morrey, and Y. Furuta Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice Antimicrob. Agents Chemother. 51 2007 845 851
25. K. Sleeman, V.P. Mishin, V.M. Deyde, Y. Furuta, A.I. Klimov, and L.V. Gubareva In vitro antiviral activity of favipiravir (t-705) against drug-resistant influenza and 2009 A(H1N1) viruses Antimicrob. Agents Chemother. 54 2010 2517 2524
26. Smee, D.F., Bailey, K.W., Wong, M.H., Barnard, D.L., Furuta, Y., Sidwell, R.W., 2007. In vivo virus-inhibitory effects of T-705 against influenza A and B virus strains. In: IX International Symposium on Respiratory Viral Infections. Hong Kong 2007; March. 3-6.
27. D.F. Smee, B.L. Hurst, H. Egawa, K. Takahashi, T. Kadota, and Y. Furuta Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells J. Antimicrob. Chemother. 64 2009 741 746
28. D.F. Smee, B.L. Hurst, M.H. Wong, K.W. Bailey, E.B. Tarbet, J.D. Morrey, and Y. Furuta Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice Antimicrob. Agents Chemother. 54 2010 126 133
29. D.G. Streeter, J.T. Witkowski, G.P. Khare, R.W. Sidwell, R.J. Bauer, R.K. Robins, and L.N. Simon Mechanism of action of 1-D-ribofuranosyl-1,2,4-triazole- 3-carboxamide (Virazole), a new broad-spectrum antiviral agent Proc. Natl. Acad. Sci. USA 70 1973 1174 1178
30. K. Takahashi, Y. Furuta, Kuno M. Fukuda, T. Kamiyama, K. Kozaki, N. Nomura, H. Egawa, S. Minami, and K. Shiraki In vitro and in vivo activities of T-705 and oseltamivir against influenza virus Antivir. Chem. Chemother. 14 2003 235 241
31. K. Takahashi, D.F. Smee, K. Shiraki, Y. Kawaoka, and Y. Furuta Pharmacological effects of favipiravir, an anti-influenza viral drug. J. Med. Pharm. Sci. 66 2011 429 441 (Japanese) Jpn.
32. E.B. Tarbet, M. Maekawa, Y. Furuta, Y.S. Babu, J.D. Morrey, and D.F. Smee Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice Antiviral Res. 94 2012 103 110
33. T. Watanabe, M. Kiso, S. Fukuyama, N. Nakajima, M. Imai, S. Yamada, S. Murakami, S. Yamayoshi, K. Iwatsuki-Horimoto, Y. Sakoda, E. Emi Takashita, R. McBride, T. Noda, M. Hatta, H. Imai, D. Zhao, N. Kishida, M. Shirakura, R.P. de Vries, S. Shichinohe, M. Okamatsu, T. Tamura, Y. Tomita, N. Fujimoto, K. Goto, H. Katsura, E. Kawakami, I. Ishikawa, S. Watanabe, M. Ito, Y. Yuko Sakai-Tagawa, Y. Sugita, R. Uraki, R. Yamaji, A.J. Eisfeld, G. Zhong, S. Fan, J. Ping, E.A. Maher, A. Hanson, Y. Uchida, T. Saito, M. Ozawa, G. Neumann, H. Kida, T. Odagiri, J.C. Paulson, H. Hasegawa, M. Tashiro, and Y. Kawaoka Characterization of H7N9 influenza A viruses isolated from humans Nature 2013 10.1038/nature12392 Published online 10 July 2013